Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene
Oak, Ninad , Chen, Wenan , Blake, Alise K. , Harrison, Lynn , O’Brien, Martha A., Previti, Christopher , Balasubramanian, Gnanaprakash, Hirsch, Steffen , Penkert, Judith , Jones, Barbara C. , Schramm, Kathrin , Nathrath, Michaela , Witt, Olaf , Li, Jiaming , Ness, Kirsten K. , Kratz, Christian P. , Armstrong, Greg , Autry, Robert J. , Nichols, Kim E. , Armstrong, Gregory T. , Blake, Alise , Hirsch, Steffen , Penkert, Judith , Jones, Barbara C , Nathrath, Michaela , Pajtler, Kristian W , Jones, David T W , Witt, Olaf , Dirksen, Uta , Li, Jiaming , Sapkota, Yadav , Ness, Kirsten K , Guenther, Lillian M , Kratz, Christian , Wang, Zhaoming , Hudson, Melissa M , Wu, Gang , Nichols, Kim E , Sharma, Richa , O'Brien, Martha, Maaß, Kendra K. , Pajtler, Kristian W. , Jones, David , Sapkota, Yadav , Pfister, Stefan M. , Wang, Zhaoming , Hudson, Melissa M. , Wu, Gang , Sharma, Richa

Mayo Clinic

Journal of Clinical Oncology | October 9, 2025 | Volume: 43 | Issue: 36 | Pages: 3833-3843

10.1200/jco-25-01114 | PMID 41066719 Get It

PURPOSE Recent studies reveal that 5%-18% of children with cancer harbor pathogenic variants in known cancer-predisposing genes. However, DNA damage repair (DDR) genes, which are frequently somatically altered in pediatric tumors, have not been systematically examined as a source of novel cancer-predisposing signals. METHODS To address this gap, we interrogated 189 DDR genes for presence of germline predisposing variants (PV) among 5,993 childhood cancer cases and 14,477 adult noncancer controls (discovery cohort). PV were determined using a tiered approach incorporating ClinVar annotations, InterVar classification, and in silico tools (REVEL, CADD, and MetaSVM). Using logistic and firth regression, we identified genes with PV statistically enriched in the germline of children with tumors and replicated findings among 1,497 additional childhood cancer cases across three independent cohorts. RESULTS Analysis across all cases with cancer revealed enrichment of TP53 PV. Cancer-specific analyses confirmed known associations including germline TP53 PV in adrenocortical carcinoma, high-grade glioma (HGG), and medulloblastoma (MB), PMS2 in HGG and non-Hodgkin lymphoma (NHL), MLH1 in HGG, BRCA2 in NHL, and BARD1 in neuroblastoma. In addition, four novel associations were uncovered, including BRCA1 in ependymoma, SPIDR in HGG, SMC5 in MB, and SMARCAL1 in osteosarcoma (OS). Importantly, the SMARCAL1 :OS association was significant in the discovery (6/230, 2.6%, false discovery rate [FDR] logistic = 0.0189) as well as all three replication cohorts (Childhood Cancer Survivor Study: 8/275, 2.9%; P Fisher < .0001; Cancer Predisposition Syndrome-German Childhood Cancer Registry: 4/135, 3%, P Fisher = .002; Individualized Therapy for Relapsed Malignancies in Childhood: 4/217, 1.8%, P Fisher = .012). The remaining wild-type SMARCAL1 allele was deleted in three of four OS tumors with available data. CONCLUSION Our study confirms the relevance DDR genetic variation in pediatric cancer risk and establishes SMARCAL1 as a novel OS predisposing gene, providing insights into tumor biology and creating opportunities to optimize care for patients with this challenging tumor.
Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high-grade IDH mutant gliomas
Sears, Thomas , Wang, Wenxia , Steffens, Alicia , McCortney, Kathleen , Horbinski, Craig , Horbinski, Craig , McCortney, Kathleen , Sears, Thomas , McCord, Matthew , Chaliparambil, Rahul Kishore , Sarkaria, Jann N.

Mayo Clinic

JCI Insight | October 9, 2025 | Volume: 10 | Issue: 22 | Pages: No page available

10.1172/jci.insight.195385 | PMID 41066183 Get It

IDH1/2 mutations (IDH mut ) increase methylation of DNA and histones in gliomas. IDH mut inhibitors are effective against low-grade IDH mut gliomas, but new strategies against high-grade IDH mut gliomas are needed. Although histone deacetylase inhibitors (HDACi) are ineffective against IDH wt glioblastoma (GBM), their potential in IDH mut gliomas has not been extensively studied. We previously established that IDH mut gliomas are more sensitive to HDACi than IDH wt GBM. Here we show that IDH mut is associated with greater sensitivity to HDACi only in glioma, not in IDH mut chondrosarcoma or cholangiocarcinoma. While HDACi induced more histone acetylation and gene regulation in IDH mut glioma than in IDH wt GBM, such acetylation was mostly within gene deserts, whereas IDH mut glioma promoters paradoxically lost histone acetylation. Two mediators of HDACi resistance, YAP and TAZ, were methylated and suppressed in IDH mut gliomas but not in other IDH mut cancers. Inducing YAP or TAZ expression in IDH mut gliomas conferred resistance to HDACi. Finally, belinostat extended in vivo survival only in IDH mut glioma models, not in IDH mut GBM models. Our findings provide a mechanistic rationale for further studies of HDACi in patients with IDH mut glioma, as well as the potential use of YAP/TAZ as a biomarker of HDACi sensitivity in cancers.
Strengthening Physical Medicine and Rehabilitation Departmental Research: Insights From the Association of Academic Physiatrists Research Consulting Program
Wang, Qing Mei , Lencioni, Stephen, Huber, Justin , Rizzo, John‐Ross , Scholten, Paul , Swanson, Randel L. , Schnappinger, Amy, Arnold, W David , Annaswamy, Thiru M. , Bean, Allison , Kumbhare, Dinesh Arun , Li, Sheng , Paganoni, Sabrina , Suskauer, Stacy J. , Whyte, John , Arnold, W. David

Mayo Clinic

American Journal of Physical Medicine & Rehabilitation | October 9, 2025 | Volume: 104 | Issue: 12 | Pages: 1186-1189

10.1097/phm.0000000000002769 | PMID 41065593 Get It

Abstract Clinical and translational research is important for health care and the growth of medical specialties. Physical medicine and rehabilitation offers many opportunities for research, but research growth in physical medicine and rehabilitation is lacking, and research resources and productivity vary across academic physical medicine and rehabilitation departments across North America. The Physiatric Research Consulting Program was developed by the Association of Academic Physiatrists to provide customized recommendations to enhance research capacity and productivity in physical medicine and rehabilitation departments. This report outlines the three components of the Physiatric Research Consulting Program, including a previsit needs assessment, an in-person visit, and a postvisit follow-up final report. The report also provides a qualitative assessment of the impact of the Physiatric Research Consulting Program, with general themes of feedback, site visit evaluations, and final report evaluations. The Physiatric Research Consulting Program was found to be valuable in identifying gaps and needs for physical medicine and rehabilitation departments, providing outside perspectives, and energizing faculty toward research growth in their departments.
Clinical Features of Chinese Patients with Thyroid Eye Disease: A Multicenter Retrospective Study
Lei, Chaoyu , Lyu, Xukun, Ren, Yujie , Wei, Dingwei, Zhang, Siyuan , Zhang, Yuwei , Wang, Liu , Liu, Libin , Liu, Xiaowei , Lin, Chaobin, Lu, Wei , Li, Runchuan , Zhang, Shuo , Song, Xuefei, Yu, Zhangsheng, Bahn, Rebecca S. , Zhou, Huifang, Lyu, Xukun, Wei, Dingwei, Wen, Junping , Liu, Jianjun , Song, Xuefei

Mayo Clinic

Thyroid® | October 8, 2025 | Volume: 35 | Issue: 10 | Pages: 1187-1197

10.1177/10507256251359559 | PMID 40658134 Get It

Background: Thyroid eye disease (TED) is a debilitating autoimmune disorder linked to thyroid dysfunction. There is limited knowledge of TED in Asian populations. This multicenter study characterizes the clinical features and treatment response of TED in a large Chinese cohort. Methods: A retrospective multicenter study included 4157 patients with TED from nine Chinese hospitals from February 2016 to July 2023. Disease severity and activity were evaluated according to the European Group on Graves’ Orbitopathy standards. We examined associations of variables including sex, age, smoking status, I 131 treatment, consultation department, and geographical region with clinical outcomes. Logistic regression and nomogram models were developed to examine associations with sight-threatening TED and, in a subgroup analysis ( n = 126), patients’ responsiveness to intravenous glucocorticoid (IVGC) therapy. Results: We included 4157 patients with mean age and standard deviation (SD) 45.96 ± 16.44 years. Of these, 63.6% ( n = 2644) were females. Over half (55.6%, n = 2310) of participants were in the inactive phase, with a mean clinical activity score of 2.19 ± 1.61 (SD) for all patients. TED severity was categorized as mild (9.3%, n = 385), moderate-to-severe (82.5%, n = 3428), and sight-threatening (8.2%, n = 344). The average degree of exophthalmos was 20.04 ± 5.27 mm, and 48.8% ( n = 2029) of patients had diplopia. Patients treated with I 131 had higher disease activity (47.5%, n = 468, vs. 43.5%, n = 1379, p < 0.05). Coastal region patients exhibited more severe TED (sight-threatening cases: 10.1%, n = 195, vs. 7.2%, n = 147) and higher diplopia scores (1.00 ± 1.10 vs. 0.86 ± 1.09, p < 0.001) than inland counterparts. TED severity was also greater in patients treated in Ophthalmology departments (mild cases: 6.0%, n = 213; moderate-to-severe cases: 85.6%, n = 3055) compared with Endocrinology departments (mild cases: 29.3%, n = 172; moderate-to-severe cases: 63.5%, n = 373). Nomograms had an area under the receiver operating curve of 0.742 (confidence interval [CI] 0.716–0.768) for sight-threatening TED and 0.759 (CI 0.674–0.843) for IVGC therapy responsiveness. Conclusions: We characterized the clinical features and treatment response of TED in a large Chinese cohort. These findings offer valuable insights informing TED risk stratification in Asian patients and forming a foundation for future prospective studies.
CRISPR activation of the ribosome-associated quality control factor ASCC3 ameliorates fragile X syndrome phenotypes in mice
Geng, Ji , Pan, Jie , Khan, Danish , Pimcharoen, Sopida, Zhang, Yong‐Jie , Mosammaparast, Nima , Hirose, Susumu, Petrucelli, Leonard , Brandman, Onn , Qi, Lei S. , Pimcharoen, Sopida , Zhang, Yong-Jie , Mosammaparast, Nima , Petrucelli, Leonard , Brandman, Onn , Lu, Bingwei , Wang, Xiying , Lu, Bingwei

Mayo Clinic

Science Translational Medicine | October 8, 2025 | Volume: 17 | Issue: 819 | Pages: No page available

10.1126/scitranslmed.adq3551 | PMID 41061044 Get It

Loss of fragile X messenger ribonucleoprotein (FMRP) causes fragile X syndrome (FXS), an inherited neurodevelopmental disorder resulting in intellectual disability and autism spectrum disorder; however, the molecular function of FMRP remains uncertain. Here, using cell lines and fibroblasts and induced pluripotent stem cell–derived neurons from healthy individuals and patients with FXS, we showed that FMRP regulates collided ribosomes by recruiting activating signal cointegrator 1 complex subunit 3 (ASCC3), an early-acting ribosome-associated quality control (RQC) factor to collided ribosomes, and either positively or negatively regulating translation, depending on transcript context. Disease-associated ASCC3 variants that perturbed ASCC3-FMRP interaction were also found to be defective in ribosome association and handling of collided ribosomes. In cells of a patient with FXS and the Fmr1 KO mouse model, ASCC3 abundance was reduced, and overexpression of ASCC3 in the brains of fetal Fmr1 KO mice promoted neuronal migration. In addition, CRISPR-mediated activation of ASCC3 by lateral ventricular injection of adeno-associated virus (AAV) ameliorated synaptic defects and improved locomotor activity, cognitive deficits, obsessive-compulsive–like behavior, and social interaction deficits after 1 month in 2-month-old Fmr1 KO mice compared with untreated Fmr1 KO controls. In conclusion, these data implicated FMRP in the handling of collided ribosomes to maintain protein homeostasis during neurodevelopment and synaptogenesis and demonstrated proof of concept that targeting RQC may offer alternative treatment strategies for FXS.
Abstract Thu133: Discovery of a Novel Compound Targeting CDCP1 to Modulate Human Cardiac Fibrosis
Srinivas, Akshatha Narayanrao, Wang, Min , Zhang, Heyu , Weber, Caleb, Islam, Naeyma N., Fuller, Jessica , Lambert, Laura , Weinshilboum, Richard M. , Pereira, Naveen L. , Ghazal, Rachad , Srinivas, Akshatha Narayanrao, Selvaraj, Manikandan , Marín-Goñi, Irene , Coban, Matt , Weber, Caleb, Fuller, Jessica, Liu, Duan , Lambert, Laura, Weinshilboum, Richard M. , Caulfield, Thomas R.

Mayo Clinic

Circulation Research | October 8, 2025 | Volume: 137 | Issue: Suppl_1 | Pages: No page available

10.1161/res.137.suppl_1.thu133 Get It

Background: Cardiac fibrosis is a central pathological process that leads to worse outcomes in various cardiomyopathies. Recent evidence shows that CDCP1 (CUB domain-containing protein 1) modulates myocardial recovery by attenuating human cardiac fibroblast (HCF) proliferation. This study investigates the hypothesis that selective targeting of the CDCP1 cleavage domain can mitigate fibroblast proliferation, thereby offering a novel therapeutic approach to reducing cardiac fibrosis. Methods: A high-throughput in silico screening was performed using the Enamine compound library, focusing on structural regions that include the cleavage and adjacent sites of CDCP1 . A total of 147 candidate compounds were prioritized based on docking scores and binding stability profiles. Selected compounds were subsequently evaluated in vitro using HCF cultures seeded at 3,000 cells/well in 96-well plates. Each compound was administered at 10 μM concentration, and cell proliferation and viability were assessed by time-lapse imaging in the Incucyte® system at 24 and 96 hours. All experiments were done in triplicate with appropriate DMSO vehicle controls. Results: Compound C3 significantly reduced HCF proliferation (Fig B) to 27.3±2.4% relative to DMSO controls (99.9±0.5%, P <0.001) at 96 hours. Detailed structural modeling indicated that C3 binds to the CDCP1 cleavage site (Fig C) with a favorable Glide XP docking score of -7.66 kcal/mol. The interaction is stabilized by hydrogen bonds with Lys365 and Cys374 (Fig D), and supplementary hydrophobic interactions between aromatic rings and aliphatic groups, which contribute to a strong inhibitory effect. Conclusion: Targeting the CDCP1 cleavage domain with compound C3 effectively diminishes HCF proliferation in vitro. Therefore, these results substantiate the therapeutic potential of CDCP1 inhibition in cardiac fibrosis. Ongoing in vivo studies will explore the translational relevance of these findings.
Discovery and Validation of Molecular Biomarkers for Differentiation of Nondysplastic Barrett’s Esophagus from High-grade Dysplasia and Esophageal Adenocarcinoma
Matchett, Caroline L. , Taylor, William R. , Berger, Calise K. , Anderson, Caryn E., Passe, Melissa, Lansing, Ramona, Wang, Panwen , Chalmers, Collin E., Foote, Patrick H. , Eckel‐Passow, Jeanette E. , Codipilly, Don C. , Leggett, Cadman L. , Ramirez, Francisco C. , Wolfsen, Herbert C. , Eluri, Swathi , Konda, Vani J. , Iyer, Prasad G. , Slettedahl, Seth W , Taylor, William R , Berger, Calise K , Anderson, Caryn E , Passe, Melissa A , Lansing, Ramona M , Wang, Panwen , Chalmers, Collin E , Foote, Patrick H , Eckel-Passow, Jeanette E , Sun, Zhifu , Mahoney, Douglas W , Codipilly, Don Chamil , Leggett, Cadman L , Ramirez, Francisco C , Kahn, Allon , Wolfsen, Herbert C , Eluri, Swathi , Konda, Vani , Trindade, Arvind J , Iyer, P G , Kisiel, John B , Slettedahl, Seth W. , Sun, Zhifu , Mahoney, Douglas W. , Kahn, Allon , Trindade, Arvind J. , Kisiel, John B.

Mayo Clinic

Cancer Prevention Research | October 8, 2025 | Volume: 19 | Issue: 1 | Pages: 49-60

10.1158/1940-6207.capr-25-0215 | PMID 41059926 Get It

Abstract Aberrant DNA methylation and copy-number alterations (CNA) drive Barrett’s esophagus progression to esophageal adenocarcinoma; however, their combined utility for early detection is unclear. We aimed to identify and validate methylated DNA markers (MDM) and CNAs to distinguish esophageal adenocarcinoma/high-grade dysplasia (HGD) from nondysplastic Barrett’s esophagus (NDBE). In this multiphase, multicenter study, we discovered and validated MDMs and quantified CNAs utilizing whole-genome methylation sequencing of esophageal brushings. DNA biomarkers identified from discovery were further validated in independent patients with paired esophageal brushing and swallowed capsule sponge samples. MDMs were filtered against a reduced representation bisulfite sequencing dataset obtained from independent tissue samples to advance only concordant candidates. CNA burden was quantified using ichorCNA-derived aneuploidy scores (AS). Two hundred MDMs discovered in HGD (N = 18) and esophageal adenocarcinoma (N = 18) versus NDBE brushing samples (N = 18) were tested in independent samples (N = 146). A 52-MDM panel achieved a cross-validated AUC of 0.88 [95% confidence interval (CI), 0.82–0.95]; the addition of AS improved discrimination of HGD/esophageal adenocarcinoma from NDBE to 0.91 (95% CI, 0.86–0.97) AUC. At 80% specificity, the combined model detected 93% of esophageal adenocarcinoma and 88% of HGD cases. In paired capsule sponge samples, a 58-MDM panel achieved a cross-validated AUC of 0.77 (95% CI, 0.66–0.88); a combined 58-MDM and AS model achieved AUC 0.80 (95% CI, 0.7–0.9). MDMs and AS discerned HGD/esophageal adenocarcinoma from normal esophagus/NDBE in endoscopic brushing and capsule sponge samples. This approach may improve Barrett’s esophagus surveillance. Prevention Relevance: This study demonstrates that combining epigenetic and genomic biomarkers across minimally invasive sampling methods can accurately distinguish HGD/esophageal adenocarcinoma from nondysplastic Barrett’s esophagus, offering promising, less invasive strategies to improve BE surveillance and enable endoscopic therapy for esophageal adenocarcinoma prevention and treatment.
The Protein Tyrosine Phosphatase 1B Modulates the Activation of Yes-Associated Protein and Sensitizes to Cytotoxic Chemotherapy in Preclinical Models of Cholangiocarcinoma
Watkins, Ryan , Tomlinson, Jennifer L. , Buckarma, EeeLN H. , Carlson, Danielle M. , Werneburg, Nathan W., O’Brien, Daniel R. , Smoot, Rory L. , Watkins, Ryan D, Kuipers, Hendrien , O'Brien, Daniel R, Smoot, Rory L , Tomlinson, Jennifer , Carlson, Danielle Marie , Wang, Chen

Mayo Clinic

Cells | October 8, 2025 | Volume: 14 | Issue: 19 | Pages: 1560

10.3390/cells14191560 | PMID 41090788 Get It

Lacking effective therapeutics, cholangiocarcinoma (CCA) remains a deadly malignancy of the biliary tract. The Hippo pathway effector protein Yes-associated protein (YAP) is implicated in CCA pathogenesis and chemotherapeutic resistance; however, the oncogenic mechanisms underlying YAP regulation remain incompletely understood. An enhanced understanding of YAP and its role in CCA may uncover novel therapeutic targets and better define resistance pathways. Human CCA cells and murine syngeneic CCA models were utilized to explore the molecular relationship of YAP and protein tyrosine phosphatase 1B (PTP1B). Previous work in CCA has demonstrated that YAP interacts with multiple protein tyrosine phosphatases, including SHP2 and PTP1B. We observed that PTP1B pharmacologic inhibition was associated with increased cell proliferation and YAP target gene expression, while genetically enforced overexpression of PTP1B was associated with a decrease in YAP activation. Treatment of CCA cells in vitro and syngeneic, orthotopically implanted CCA murine tumors in vivo with standard cytotoxic chemotherapy, gemcitabine/cisplatin, had enhanced efficacy in the setting of PTP1B overexpression. These findings demonstrate that pYAPY357 can be modulated through protein tyrosine 1B phosphatase activity, and reducing pYAPY357 through enhanced phosphatase levels can sensitize CCA to chemotherapy.
Novel differentially expressed genes and multiple biological pathways for Alzheimer's disease identified in brain tissue from African American donors
Labadorf, Adam , O’Neill, Nicholas K. , Dugger, Brittany N. , Frosch, Matthew P. , Gearing, Marla, Jin, Lee‐Way, Kofler, Julia , Mayeux, Richard , McKee, Ann C. , Miller, Carol A., Murray, Melissa E. , Nelson, Peter T. , Perrin, Richard J. , Tobunluepop, Katarnut, Troncoso, Juan C. , Murray, Melissa E , Dugger, Brittany N , Logue, Mark W. , Dickson, Dennis W. , Flanagan, Margaret E. , Gearing, Marla , Schneider, Julie A. , Stein, Thor D. , Teich, Andrew F. , Wang, Shih‐Hsiu J. , Wang, Zihan , Wolozin, Benjamin , Mez, Jesse , Farrer, Lindsay A.

Mayo Clinic

Alzheimer's & Dementia | October 8, 2025 | Volume: 21 | Issue: 10 | Pages: No page available

10.1002/alz.70629 | PMID 41059714 Get It

Abstract INTRODUCTION Few African American (AA) donors have been included in post mortem Alzheimer's disease (AD) studies compared to European‐ancestry (EA) individuals. METHODS We generated transcriptome‐wide bulk pre‐frontal cortex (PFC) gene expression data from 125 AA donors with neuropathologically determined AD and 82 AA controls. RESULTS Transcriptome‐wide significant differential expression was observed with 482 genes. The most significant, ADAMTS2 , showed 1.52 times higher expression in AD cases ( p = 2.96x10 −8 ). Comparison of findings with those from a recent gene expression study of EA brain donors revealed substantial concordance, including ADAMTS2 . Other associations not observed in EA results may be especially relevant to AD risk in the AA population. Examination of AA AD GWAS‐implicated variants identified several expression quantitative trait loci. CONCLUSION This first large‐scale AA brain AD gene expression study identified many differentially expressed genes, including ADAMTS2 , and supports gene expression as a molecular pathway underlying the impact of several AA AD risk variants. Highlights We performed the largest African American brain tissue Alzheimer's disease (AD) gene expression study. Expression differences for 482 genes, notably ADAMTS2 , were study‐wide significant. Many significant differentially expressed genes are involved in energy metabolism. Several previously known AD‐associated variants in African Americans are eQTLs. These results advance knowledge of the genetic basis of AD in the AA population.
Complications From Cochlear Implantation and Management of Noncholesteatoma Chronic Otitis Media With Perforation: A Systematic Review and Meta-analysis
Rendon, Eric Delgado , Wilson, Prishae, Kabat, Natalia M., Rosasco, Robyn , Raymond, Mallory , Wilson, Penny , Delgado Rendon, Eric , Wilson, Prishae , Wilson, Prishae, Wang, Zhen , Raymond, Mallory J

Mayo Clinic

Otology & Neurotology | October 8, 2025 | Volume: 47 | Issue: 1 | Pages: 132-138

10.1097/mao.0000000000004651 | PMID 41058027 Get It

Objective: To compare postoperative complications between staged versus unstaged tympanoplasty and subtotal petrosectomy (STP) in adults undergoing cochlear implants with noncholesteatoma chronic otitis media (NCCOM) and tympanic membrane perforation. Databases reviewed: PubMed/MEDLINE, Cochrane CENTRAL, Embase, CINAHL, Web of Science, WHO Global Index Medicus, ClinicalTrials.gov, and WHO ICTRP. Materials and methods: A systematic search of databases was conducted by a research librarian from inception through November 18, 2024. Eligible studies for inclusion must have reported on adult cochlear implant recipients undergoing surgical management of NCCOM with perforation. Using a random effects model, complication rates were pooled and compared between staged and unstaged surgeries using relative risk (RR) with 95% CI. Results: Of 1265 studies identified, 19 met inclusion criteria (n = 84). Fifty three (63.1%) patients underwent unstaged surgery. Amongst all patients, STP was performed more than tympanoplasty (72.6%, 61/84 vs 27.4%, 23/84), and the overall complication rate was 11.9% (10/84). There was no significant difference in complication rates between combined staged and unstaged surgeries [RR: 1.13 (95% CI, 0.18-7.04)] as well staged and unstaged tympanoplasty [RR: 0.34 (95% CI, 0.11-0.1.01)]. However, complication rates were lower for staged than unstaged STP [RR: 0 (95% CI, 0.0-0.07)]. Conclusion: Staged and unstaged surgery for NCCOM and cochlear implant may result in comparable complication rates, however the wide CIs for RR statistics in comparisons between combined staged and unstaged procedures as well as staged and unstaged tympanoplasty indicate a need for similar studies of larger populations.